相关实验视频
Updated: Jul 12, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
在接受免疫检查点抑制剂的癌症患者中的肺炎肠道病
Gabriel Sperling1, Malek Shatila2, Krishnavathan Varatharajalu2
1School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
肺炎肠道 (PI),一种罕见的免疫相关不良事件 (irAE),可以发生在免疫检查点抑制剂 (ICI) 治疗后. 虽然PI通常无症状,但可能需要抗生素和观察,癌症治疗通常会在之后恢复.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 免疫检查点抑制剂 (ICI) 是关键的癌症疗法.
- 免疫相关不良事件 (irAEs) 是已知的ICI治疗并发症.
- 肠道肺炎 (PI),或肠壁中的气体,是ICI使用后罕见的发现,意义不明.
研究的目的:
- 描述ICI治疗的癌症患者PI的临床特征和结果.
- 评估PI作为一个潜在的irAE.
主要方法:
- 对12名成年癌症患者的回顾性分析,在ICI暴露一年内有PI的放射性证据.
- 评估临床特征,治疗和结果.
主要成果:
- 平均年龄为64岁;常见的癌症包括胸部/头和胃肠道.
- 大多数患者接受了抗PD-1/L1单一治疗;PI发生的中位数为ICI后7个月.
- 一半的患者无症状;腹痛是最常见的症状. 这些并发症包括肺 (50%) 和微孔 (8%).
- 九名患者接受了抗生素治疗;三名患者得到了保守的监测. 九名患者恢复了癌症治疗.
结论:
- 在ICI治疗后,PI可以表现为irAE.
- 抗生素治疗和观察甚至适用于偶然的PI发现.
- 需要进一步的研究来澄清PI-ICI关联,并指导癌症治疗的重新启动.
更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
相关概念视频
Tumor Immunotherapy
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumothorax-II
Clinical Manifestations:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia II: Pathophysiology